D A Mankoff

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Imaging in breast cancer - breast cancer imaging revisited
    David Mankoff
    Breast Cancer Res 7:276-8. 2005
  2. ncbi Are we ready for dedicated breast imaging approaches?
    David A Mankoff
    Division of Nuclear Medicine, Box 356113, Room NN203, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 44:594-5. 2003
  3. ncbi Tumor receptor imaging
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
    J Nucl Med 49:149S-63S. 2008
  4. ncbi [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002
  5. ncbi Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy
    David A Mankoff
    Seattle Cancer Care Alliance, Radiology, 2nd Floor, 825 Eastlake Avenue East, PO Box 19023, Seattle, WA 98109, USA
    Acad Radiol 14:398-405. 2007
  6. ncbi Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond
    David A Mankoff
    University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, USA
    Clin Cancer Res 13:3460-9. 2007
  7. ncbi Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy
    David A Mankoff
    Division of Nuclear Medicine, Box 346113, University of Washington, 1959 E Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 43:500-9. 2002
  8. ncbi Proliferation imaging to measure early cancer response to targeted therapy
    David A Mankoff
    Department of Radiology, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 14:7159-60. 2008
  9. ncbi Molecular imaging to select cancer therapy and evaluate treatment response
    D A Mankoff
    Seattle Cancer Care Alliance and University of Washington, Seattle, WA 98102, USA
    Q J Nucl Med Mol Imaging 53:181-92. 2009
  10. ncbi Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003

Research Grants

  1. PET to Measure Breast Cancer Bone Metastasis Response
    David Mankoff; Fiscal Year: 2009
  2. PET to Measure Breast Cancer Bone Metastasis Response
    David Mankoff; Fiscal Year: 2007
  3. IMAGING THE RESPONSE OF LOCALLY ADVANCED BREAST CANCER
    David Mankoff; Fiscal Year: 2006
  4. Diagnosis of IM Nodal Metastases in Breast Cancer
    David Mankoff; Fiscal Year: 2004
  5. IMAGING THE RESPONSE OF LOCALLY ADVANCED BREAST CANCER
    David Mankoff; Fiscal Year: 2000
  6. PET to Measure Breast Cancer Bone Metastasis Response
    David A Mankoff; Fiscal Year: 2010

Detail Information

Publications80

  1. ncbi Imaging in breast cancer - breast cancer imaging revisited
    David Mankoff
    Breast Cancer Res 7:276-8. 2005
  2. ncbi Are we ready for dedicated breast imaging approaches?
    David A Mankoff
    Division of Nuclear Medicine, Box 356113, Room NN203, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 44:594-5. 2003
  3. ncbi Tumor receptor imaging
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
    J Nucl Med 49:149S-63S. 2008
    ....
  4. ncbi [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002
    ..To determine the influence of breast tumor blood flow on MIBI kinetics, we compared MIBI uptake and washout to [O-15]-water PET estimates of blood flow in patients with locally advanced breast cancer...
  5. ncbi Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy
    David A Mankoff
    Seattle Cancer Care Alliance, Radiology, 2nd Floor, 825 Eastlake Avenue East, PO Box 19023, Seattle, WA 98109, USA
    Acad Radiol 14:398-405. 2007
  6. ncbi Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond
    David A Mankoff
    University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, USA
    Clin Cancer Res 13:3460-9. 2007
    ....
  7. ncbi Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy
    David A Mankoff
    Division of Nuclear Medicine, Box 346113, University of Washington, 1959 E Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 43:500-9. 2002
    ....
  8. ncbi Proliferation imaging to measure early cancer response to targeted therapy
    David A Mankoff
    Department of Radiology, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 14:7159-60. 2008
    ....
  9. ncbi Molecular imaging to select cancer therapy and evaluate treatment response
    D A Mankoff
    Seattle Cancer Care Alliance and University of Washington, Seattle, WA 98102, USA
    Q J Nucl Med Mol Imaging 53:181-92. 2009
    ..The use of imaging to measure early pharmacodynamic changes and subsequent response to cancer treatment is then reviewed. Finally, the need for standardization and reproducible quantitative imaging analysis is reviewed...
  10. ncbi Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
    ..To characterize in vivo tumor biology in patients with LABC, we performed serial measurements of blood flow and glucose metabolism in LABC patients over the course of neoadjuvant chemotherapy and compared measurements with response...
  11. ncbi PET imaging of cellular proliferation
    David A Mankoff
    Division of Nuclear Medicine, Department of Radiology, University of Washington, 1959 Northeast Pacific Street, Room NN203, Box 356113, Seattle, WA 98195, USA
    Radiol Clin North Am 43:153-67. 2005
    ....
  12. ncbi Positron-emission tomographic imaging of cancer: glucose metabolism and beyond
    D A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Semin Radiat Oncol 11:16-27. 2001
    ..Finally, preliminary studies using PET tracers with greater specificity than FDG for tumor imaging are discussed. Emphasis is placed on underlying principles and those aspects of oncologic PET most applicable to radiation oncology...
  13. ncbi Molecular imaging as a tool for translating breast cancer science
    David A Mankoff
    Seattle Cancer Care Alliance and University of Washington, Radiology, Seattle, WA 98109, USA
    Breast Cancer Res 10:S3. 2008
    ..Work in both animal models and human is discussed with an eye towards studies that have relevance to breast cancer treatment in patients...
  14. ncbi Current and future uses of positron emission tomography in breast cancer imaging
    William B Eubank
    Department of Radiology, Puget Sound VA Health Care System, Seattle, WA 98108-1597, USA
    Semin Nucl Med 34:224-40. 2004
    ..Future work using other PET tracers besides FDG will undoubtedly help our understanding of tumor biology, improve our ability to measure and predict response and help tailor therapy to individual patients...
  15. ncbi 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy
    Jeffrey Tseng
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195-6113, USA
    J Nucl Med 45:1829-37. 2004
    ..Further work is needed to understand the tumor biology underlying these findings...
  16. ncbi 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer
    W B Eubank
    Department of Radiology, University of Washington School of Medicine, Seattle, USA
    J Clin Oncol 19:3516-23. 2001
    ....
  17. ncbi Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography
    S Eyal
    Department of Pharmaceutics, University of Washington, Seattle, Washington, USA
    Clin Pharmacol Ther 87:579-85. 2010
    ..Our results indicate that P-gp and its inhibition equally affect the distribution of drugs (and therefore their neuro-efficacy and toxicity) in the various brain regions protected by the BBB...
  18. ncbi Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer
    Michelle S Yao
    Department of Radiation Oncology, University of Washington Medical School, Seattle, WA, USA
    Ann Surg Oncol 14:2985-93. 2007
    ..Internal mammary (IM) nodes are a potential site of breast lymphatic drainage. We examined the relationship between lymphoscintigraphic evidence of IM drainage and survival in early-stage breast cancer patients (pts)...
  19. ncbi Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP)
    T J Tewson
    Department of Radiology, University of Washington Medical Center, Seattle 98195, USA
    Nucl Med Biol 26:905-13. 1999
    ..Estimates of equilibrium binding in blood samples are sufficient to characterize [18F]-FES binding to SBP in the circulation...
  20. ncbi Comparison of different quantitative approaches to 18F-fluoride PET scans
    Winfried Brenner
    Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195 6113, USA
    J Nucl Med 45:1493-500. 2004
    ..In patients imaged twice, changes in metabolic rates were determined using the different quantitation methods...
  21. ncbi Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate
    Sara Eyal
    Department of Pharmaceutics, University of Washington, Seattle, Washington, USA
    J Nucl Med 50:798-806. 2009
    ..We used (11)C-verapamil as the prototypic P-gp substrate and cyclosporine A (CsA) as the prototypic inhibitor...
  22. ncbi SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences
    Sylvain Beaulieu
    Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    J Nucl Med 44:1044-50. 2003
    ..A comparison method based on this finding appears feasible and may improve the usefulness of the SUV by providing a means of comparing SUV acquired at different times after injection...
  23. ncbi Imaging cellular proliferation as a measure of response to therapy
    K A Krohn
    Division of Nuclear Medicine, Imaging Research Laboratory Box 356004, University of Washington, Seattle, WA 98195-6004, USA
    J Clin Pharmacol . 2001
    ..Patient imaging using the PET thymidine analogs is at an earlier stage but appears promising as a clinically feasible approach to cellular proliferation imaging...
  24. ncbi Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy
    Stephanie E Stafford
    Division of Medical Oncology, University of Washington Medical Center, Seattle 98195, USA
    Acad Radiol 9:913-21. 2002
    ..01). CONCLUSION: Preliminary results indicate that serial whole-body FDG PET can help quantitatively assess the response of breast cancer bone metastases to therapy. Prospective trials are needed to further investigate its accuracy...
  25. ncbi Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
    ..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
  26. ncbi True tracers: comparing FDG with glucose and FLT with thymidine
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, 98195-6004, USA
    Nucl Med Biol 32:663-71. 2005
    ..The fidelity with which analog tracers mimic tracers of the authentic substrate is critically evaluated for [(18)F]-2-fluoro-2-deoxyglucose and [(18)F]-3'-fluoro-3'-deoxythymidine...
  27. ncbi FDG PET, PET/CT, and breast cancer imaging
    Eric L Rosen
    Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G3 200, Seattle, WA 98109 1023, USA
    Radiographics 27:S215-29. 2007
    ..PET has demonstrated a particular capability for evaluation of chemotherapy response in both patients with locally advanced breast carcinoma and those with metastatic disease...
  28. ncbi Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
    Lanell M Peterson
    Department of Radiology, University of Washington Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    J Nucl Med 49:367-74. 2008
    ..We therefore compared (18)F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures...
  29. ncbi Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation
    Kevin S Tralins
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington, USA
    J Nucl Med 43:1667-73. 2002
    ..18)F-FDG PET volumes were predictive of survival and time to tumor progression in the treatment of patients with GBM...
  30. ncbi Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:145-50. 2002
    ..Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome...
  31. ncbi Current and future use of positron emission tomography (PET) in breast cancer
    David A Mankoff
    Division of Nuclear Medicine, Department of Radiology, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
    J Mammary Gland Biol Neoplasia 11:125-36. 2006
    ..Finally we review work done with other radiopharmaceuticals beyond FDG designed to image a number of aspects of breast cancer biology, emphasizing those most likely to enter clinical trials in the near future...
  32. ncbi Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances
    Jeffrey P Kanne
    Department of Radiology, University of Washington, Seattle, WA 98195-7115, USA
    AJR Am J Roentgenol 188:W503-5. 2007
  33. ncbi Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases
    Robert K Doot
    Division of Nuclear Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, Washington 98195 7987, USA
    J Nucl Med 51:521-7. 2010
    ..The purpose of this analysis was to evaluate the accuracy and precision of (18)F-fluoride model parameter estimates for characterizing regional kinetics in metastases and normal bone in breast cancer patients...
  34. ncbi Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Jennifer R Bellon
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
    Am J Clin Oncol 27:407-10. 2004
    ..FDG-PET appears to be a useful noninvasive modality to detect IM metastases in LABC. Pathologic verification in a prospective study is necessary to confirm these findings...
  35. ncbi Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival
    Lisa K Dunnwald
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    Cancer 103:680-8. 2005
    ..Given the association between MIBI uptake and tumor blood flow, this prognostic capability may be related to retained tumor vascularity after treatment...
  36. ncbi Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate
    F S Chung
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    Br J Pharmacol 159:394-404. 2010
    ..Therefore, using positron emission tomography (PET) imaging, we tested whether gestational age affects tissue P-gp activity in the pregnant non-human primate, Macaca nemestrina...
  37. ncbi [18F]fluoroestradiol radiation dosimetry in human PET studies
    D A Mankoff
    Departments of Radiology and Medical Oncology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 42:679-84. 2001
    ..FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits...
  38. ncbi Beyond detection: novel applications for PET imaging to guide cancer therapy
    Joseph G Rajendran
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 48:855-6. 2007
  39. ncbi Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Hannah M Linden
    Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA
    Clin Cancer Res 12:5608-10. 2006
  40. ncbi Positron emission tomography imaging as a cancer biomarker
    Evan Y Yu
    Seattle Cancer Care Alliance, Division of Medical Oncology, 825 Eastlake Avenue East, G4 836, Seattle, WA 98109, USA
    Expert Rev Mol Diagn 7:659-72. 2007
    ..In this review, we discuss cancer biomarker development, opportunities for PET to elucidate tumor biology and the potential role of PET in clinical research and practice...
  41. ncbi Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:151-9. 2002
    ..CONCLUSION: Our model adequately describes normal brain and brain tumor kinetics for thymidine and its metabolites, and it can provide an estimate of the rate of cellular proliferation in brain tumors...
  42. ncbi 18F-Fluorothymidine radiation dosimetry in human PET imaging studies
    Hubert Vesselle
    Department of Radiology, Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    J Nucl Med 44:1482-8. 2003
    ..We estimated the radiation dosimetry for this tracer from data gathered in patient studies...
  43. ncbi Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 32:1124-31. 2010
    ....
  44. ncbi Challenges in clinical studies with multiple imaging probes
    Kenneth A Krohn
    Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 34:879-85. 2007
    ..The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection...
  45. ncbi 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Cancer Res 8:971-9. 2002
    ..Changes in metabolism between the start and finish of RT, and immediate post-RT studies have received little attention...
  46. ncbi Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET
    William B Eubank
    Department of Radiology S 113 RAD, Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108 1597, USA
    Radiographics 22:5-17. 2002
    ..FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases...
  47. ncbi 18F-Fluoroestradiol
    Lavanya Sundararajan
    Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
    Semin Nucl Med 37:470-6. 2007
    ..Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight...
  48. ncbi The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging
    Jean H Lee
    Department of Radiology, Seattle Cancer Care Alliance and University of Washington, Seattle, Washington, USA
    J Nucl Med 50:569-81. 2009
    ..Part 2 will cover radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging...
  49. ncbi Adoptive T-cell therapy for the treatment of solid tumours
    Keith L Knutson
    Division of Oncology, University of Washington, 1959 NE Pacific Street, HSB BB1321, Box 356527, Seattle, WA 98195 6527, USA
    Expert Opin Biol Ther 2:55-66. 2002
    ..In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells...
  50. ncbi Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer
    Peter R Eby
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G3 200, Seattle, WA 98109 1023, USA
    Acad Radiol 15:1246-54. 2008
    ....
  51. ncbi Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 50:1267-75. 2009
    ..Here we extend the initial noncompartmental analysis of these data and apply compartmental modeling to these human verapamil imaging studies...
  52. ncbi Evolving role of positron emission tomography in breast cancer imaging
    William B Eubank
    Department of Radiology S 113 RAD, Puget Sound VA Health Care System, Seattle, WA 98108 1597, USA
    Semin Nucl Med 35:84-99. 2005
    ....
  53. ncbi Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy
    Xiaoming Chen
    Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Acad Radiol 11:1115-24. 2004
    ..We sought to determine if the combination of the two modalities was more accurate than either alone and could provide better guidance in patient management...
  54. ncbi 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 45:1653-9. 2004
    ....
  55. ncbi Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, 98195, USA
    Clin Cancer Res 10:2245-52. 2004
    ..Although acute hypoxia results in accelerated glycolysis, cellular metabolism is slowed in chronic hypoxia, prompting us to look for discordance between FMISO and FDG uptake...
  56. ncbi Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6465, USA
    J Nucl Med 46:371-80. 2005
    ..The model reflects the retention of FLT-monophosphate (FLTMP), which is generated by the phosphorylation of FLT by thymidine kinase 1 (TK1), the initial step in the exogenous pathway...
  57. ncbi Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography
    Lucy Sasongko
    Department of Pharmaceutics, Division of Nuclear Medicine, University of Washington, Seattle, WA 98195-7610, USA
    Clin Pharmacol Ther 77:503-14. 2005
    ..Our method for imaging P-gp activity can be used to identify multidrug-resistant tumors or to determine the contribution of P-gp polymorphism, inhibition, or induction to interindividual variability in drug response...
  58. ncbi [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure
    James G Douglas
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195 6043, USA
    Int J Radiat Oncol Biol Phys 64:886-91. 2006
    ..Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme...
  59. ncbi Positron emission tomography imaging of brain tumors
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, WA 98185, USA
    Neuroimaging Clin N Am 13:717-39. 2003
    ..As molecular pathways leading to and sustaining neoplasia become better understood, so will our capacity improve to measure them in vivo and intervene to the patient's advantage...
  60. ncbi [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma
    Gary N Mann
    Department of Surgery, University of Washington, Box 356410, 1959 N E Pacific Street, Seattle, Washington 98195, USA
    Ann Surg Oncol 13:187-97. 2006
    ..We evaluated whether positron emission tomography (PET) scanning with the combination of [18F]fluorodeoxyglucose (FDG) and the norepinephrine analogue [11C]metahydroxyephedrine (mHED) would allow more exact diagnosis and localization...
  61. ncbi Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression
    Robert C Rostomily
    Department of Neurological Surgery, University of Washington School of Medicine, Mailstop 356470 Room RR 744, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Head Neck 28:305-12. 2006
    ..To better define the general relevance of this imaging technique in this setting, we analyzed SSTR subtype expression in a panel of ENB tumors...
  62. ncbi Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 47:1612-21. 2006
    ..Uptake may result from retention in the biosynthetic pathway or leakage via the disrupted blood-tumor barrier. Visual analysis or static measures of 18F-FLT uptake are problematic as transport and retention cannot be distinguished...
  63. ncbi Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6465, USA
    J Nucl Med 46:274-82. 2005
    ..Compartmental modeling results were compared with simple model-independent methods of estimating FLT uptake...
  64. ncbi Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
    ..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
  65. ncbi Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
    ..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
  66. ncbi Internal mammary lymph node drainage patterns in patients with breast cancer documented by breast lymphoscintigraphy
    D R Byrd
    Department of General Surgery, University of Washington Medical Center, Seattle 98195, USA
    Ann Surg Oncol 8:234-40. 2001
    ..The purpose of this study was to identify the frequency of IMN drainage in patients undergoing breast lymphoscintigraphy and sentinel lymph node dissection (SLND)...
  67. ncbi Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF
    Robert K Doot
    Department of Bioengineering, University of Washington, Seattle, Washington, USA
    J Nucl Med 48:920-5. 2007
    ..We tested whether chemotherapy and treatment with granulocyte colony-stimulating factor (CSF) changed the blood clearance curves and therefore affected the relationship between MRFDG and SUV...
  68. ncbi Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data
    Peng Hsiao
    School of Pharmacy, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    J Pharmacol Exp Ther 317:704-10. 2006
    ..This is the first time that an in vivo CsA EC(50) of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration...
  69. ncbi Hypoxia imaging-directed radiation treatment planning
    J G Rajendran
    Department of Radiology, University of Washington, Seattle, WA 98195, USA
    Eur J Nucl Med Mol Imaging 33:44-53. 2006
    ..As a case example, we review emerging data on PET imaging of hypoxia to direct radiotherapy...
  70. ncbi Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer
    Jennifer M Specht
    Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 16:2803-10. 2010
    ..This analysis examines tumor metabolism and perfusion by tumor subtype...
  71. ncbi The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions
    Jean H Lee
    Department of Radiology, University of Washington, Seattle, Washington, USA
    J Nucl Med 50:738-48. 2009
    ..Part 2 covers radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging...
  72. ncbi Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005
    ....
  73. ncbi Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme
    Keith J Stelzer
    Celilo Radiation Therapy, Mid Columbia Medical Center, Dalles, OR, USA
    Neuro Oncol 10:88-92. 2008
    ..Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques...
  74. ncbi The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
    ..The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes...
  75. ncbi Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
    Lalitha K Shankar
    Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Nucl Med 47:1059-66. 2006
  76. ncbi Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
    David A Mankoff
    Mol Imaging Biol 5:281-5. 2003
  77. ncbi Locally advanced and inflammatory breast cancer
    Stephen Chia
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
    J Clin Oncol 26:786-90. 2008
  78. ncbi NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  79. ncbi A definition of molecular imaging
    David A Mankoff
    J Nucl Med 48:18N, 21N. 2007
  80. ncbi Medullary thyroid cancer: options for systemic therapy of metastatic disease?
    Renato G Martins
    J Clin Oncol 24:1653-5. 2006

Research Grants18

  1. PET to Measure Breast Cancer Bone Metastasis Response
    David Mankoff; Fiscal Year: 2009
    ....
  2. PET to Measure Breast Cancer Bone Metastasis Response
    David Mankoff; Fiscal Year: 2007
    ....
  3. IMAGING THE RESPONSE OF LOCALLY ADVANCED BREAST CANCER
    David Mankoff; Fiscal Year: 2006
    ..In this amended application, we focus on recent progress that has strengthened our preliminary data and further supports our proposed investigations of the biology of advanced breast cancer and its relationship to therapeutic response. ..
  4. Diagnosis of IM Nodal Metastases in Breast Cancer
    David Mankoff; Fiscal Year: 2004
    ..This diagnostic study will provide important data to direct future internal mammary radiotherapy trials. ..
  5. IMAGING THE RESPONSE OF LOCALLY ADVANCED BREAST CANCER
    David Mankoff; Fiscal Year: 2000
    ....
  6. PET to Measure Breast Cancer Bone Metastasis Response
    David A Mankoff; Fiscal Year: 2010
    ....